Interpace Biosciences Inc Anno IPO
Cos'è Anno IPO di Interpace Biosciences Inc?
Anno IPO di Interpace Biosciences Inc è 1998
Qual è la definizione di Anno IPO?
L'offerta pubblica iniziale è un tipo di offerta pubblica in cui le azioni di una società di solito sono vendute a investitori istituzionali che, a loro volta, vendono al pubblico in generale, su una borsa valori, per la prima volta.
Through IPO a privately held company transforms into a public company. Initial public offerings are mostly used by companies to raise the expansion of capital, possibly to monetize the investments of early private investors, and to become publicly traded enterprises. A company selling shares is never required to repay the capital to its public investors. After the IPO, when shares trade freely in the open market, money passes between public investors.
Although IPO offers many advantages, there are also significant disadvantages, chief among these are the costs associated with the process and the requirement to disclose certain information that could prove helpful to competitors.
The IPO process is colloquially known as going public. Details of the proposed offering are disclosed to potential purchasers in the form of a lengthy document known as a prospectus. Most companies undertake an IPO with the assistance of an investment banking firm acting in the capacity of an underwriter. Underwriters provide several services, including help with correctly assessing the value of shares.
Anno IPO di aziende nel Health Care settore su NASDAQ rispetto a Interpace Biosciences Inc
Cosa fa Interpace Biosciences Inc?
advancing patient care through molecular diagnostic testing. interpace diagnostics develops molecular diagnostic tests. our molecular diagnostic tests provide unparalleled accuracy and clarity to improve outcomes in patients facing a cancer diagnosis. you can be assured that all of the molecular tests we offer are driven by rigorous, validated science. we power the future of molecular diagnostics, delivering cutting-edge and much-needed mutational analysis that helps risk-stratify for thyroid, pancreatic, and other cancers to better inform treatment decisions. the unique molecular diagnostic tests we offer enable healthcare providers to avoid unnecessary surgeries and better assess the risk of cancer progression in their patients.
Aziende con anno ipo simili a Interpace Biosciences Inc
- Rimfire Pacific Mining NL ha Anno IPO di 1997
- Flagstar ha Anno IPO di 1997
- Active PLC ha Anno IPO di 1997
- Redflex ha Anno IPO di 1997
- Norwest NL ha Anno IPO di 1997
- Kaleyra Inc ha Anno IPO di 1997
- Interpace Biosciences Inc ha Anno IPO di 1998
- Tuesday Morning ha Anno IPO di 1999
- American Axle & Manufacturing Inc ha Anno IPO di 1999
- Liontrust Asset Management Plc ha Anno IPO di 1999
- Empire Petroleum ha Anno IPO di 1999
- Surefire Resources NL ha Anno IPO di 1999
- NXT Solutions ha Anno IPO di 1999